Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating
Oppenheimer Adjusts Entrada Therapeutics Price Target to $28 From $25, Maintains Outperform Rating
Oppenheimer将 Entrada Therapeutics 的目标价调整为 $28，从 $25，维持跑赢市场评级
Unity Software(U.US) reported fourth-quarter financial results after the market close on Monday. Here's a rundown of the report.Q4 Earnings: Unity said fourth-quarter revenue increased 35% year-over-year to $609 million, beating the consensus estimate of $562.71 million. The company reported a quarterly loss of 66 cents per share.
登录免费看全文
登录/注册
资讯热榜
更新时间